Synthon Biopharmaceuticals Reports Positive Early Results With Its Second Generation HER2-Antibody-Drug Conjugate

Best-in-Class potential with improved therapeutic index compared to other armed antibodies Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs). In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon has reported complete tumor remission...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news